Literature DB >> 21465120

Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.

Jeffrey Meyer1, Glen Balch, Christopher Willett, Brian Czito.   

Abstract

Concurrent radiation therapy and chemotherapy is the primary treatment for patients with squamous cell tumors of the anal canal, and is also employed in the neoadjuvant setting for patients with stage II and III adenocarcinoma of the rectum. There is constant clinical study involving modifications of chemoradiotherapy regimens in an effort to maximize tumor responses while reducing normal tissue toxicity. This review will discuss established regimens as well as newer and novel treatment approaches to treatment of anal and rectal cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21465120     DOI: 10.1007/s11912-011-0166-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  46 in total

1.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

2.  Combined therapy for cancer of the anal canal: a follow-up report.

Authors:  T R Buroker; N Nigro; G Bradley; L Pelok; C Chomchai; B Considine; V K Vaitkevicius
Journal:  Dis Colon Rectum       Date:  1977 Nov-Dec       Impact factor: 4.585

3.  Realization and verification of three-dimensional conformal radiotherapy with modulated fields.

Authors:  T Bortfeld; A L Boyer; W Schlegel; D L Kahler; T J Waldron
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-11-15       Impact factor: 7.038

Review 4.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

5.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

6.  Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.

Authors:  Yuji Seo; Michael T Kinsella; Harry L Reynolds; Gregory Chipman; Scot C Remick; Timothy J Kinsella
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-07       Impact factor: 7.038

7.  Mesorectal excision for rectal cancer.

Authors:  J K MacFarlane; R D Ryall; R J Heald
Journal:  Lancet       Date:  1993-02-20       Impact factor: 79.321

Review 8.  The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage.

Authors:  David J Chen; Chaitanya S Nirodi
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

9.  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

Authors:  Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher Willett
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

10.  A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy.

Authors:  G Lezoche; M Baldarelli; Mario Guerrieri; A M Paganini; A De Sanctis; S Bartolacci; E Lezoche
Journal:  Surg Endosc       Date:  2007-10-18       Impact factor: 4.584

View more
  6 in total

1.  Unusual presentation of mucinous adenocarcinoma in a post fistulectomy case.

Authors:  P J Borpujari; S Bhargava
Journal:  Med J Armed Forces India       Date:  2013-08-20

Review 2.  Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm?

Authors:  V Mandilaras; N Bouganim; J Spayne; R Dent; A Arnaout; J F Boileau; M Brackstone; S Meterissian; M Clemons
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

3.  Incidence and survival patterns of rare anal canal neoplasms using the surveillance epidemiology and end results registry.

Authors:  Cristina Metildi; Elisabeth C McLemore; Thuy Tran; David Chang; Bard Cosman; Sonia L Ramamoorthy; Sidney L Saltzstein; Georgia Robins Sadler
Journal:  Am Surg       Date:  2013-10       Impact factor: 0.688

4.  Vasculotide, an Angiopoietin-1 mimetic, reduces acute skin ionizing radiation damage in a preclinical mouse model.

Authors:  Elina Korpela; Darren Yohan; Lee Cl Chin; Anthony Kim; Xiaoyong Huang; Shachar Sade; Paul Van Slyke; Daniel J Dumont; Stanley K Liu
Journal:  BMC Cancer       Date:  2014-08-26       Impact factor: 4.430

5.  Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal Cancer.

Authors:  Jessica A Smith; Aaron T Wild; Aatur Singhi; Siva P Raman; Haoming Qiu; Rachit Kumar; Amy Hacker-Prietz; Ralph H Hruban; Ihab R Kamel; Jonathan Efron; Elizabeth C Wick; Nilofer S Azad; Luis A Diaz; Yi Le; Elwood P Armour; Susan L Gearhart; Joseph M Herman
Journal:  Int J Surg Oncol       Date:  2012-07-08

6.  Efficacy and Safety of Low-Dose-Rate Endorectal Brachytherapy as a Boost to Neoadjuvant Chemoradiation in the Treatment of Locally Advanced Distal Rectal Cancer: A Phase-II Clinical Trial.

Authors:  Shapour Omidvari; Shadi Zohourinia; Mansour Ansari; Leila Ghahramani; Mohammad Zare-Bandamiri; Ahmad Mosalaei; Niloofar Ahmadloo; Saeedeh Pourahmad; Hamid Nasrolahi; Sayed Hasan Hamedi; Mohammad Mohammadianpanah
Journal:  Ann Coloproctol       Date:  2015-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.